Nurix Therapeutics NRIX Cash Flow Statement (2019-2026)

NASDAQ NRIX
$25.83 +0.51 (+2.01%)
As of: Sep 4, 2026 · 2:25 PM EDT
Reported Financials

Nurix Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest May 2026

Nurix Therapeutics reported cash from operations of -$96.57M and free cash flow of -$97.85M for the quarter ended May 2026, down 52.9% year over year. This cash flow statement covers 28 quarters of results from Aug 2019 through May 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Feb2022 May2022 Aug2022 Nov2022 Feb2023 May2023 Aug2023 Nov2023 Feb2024 May2024 Aug2024 Nov2024 Feb2025 May2025 Aug2025 Nov2025 Feb2026 May2026
Operating Activities
Net Income
-28.84M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M-78.22M-87.17M-89.53M
Share-based CompensationStock Comp.
54.90M4.84M6.52M68.20M85.90M8.30M8.48M8.72M8.45M8.02M7.82M8.85M8.75M8.51M8.72M17.99M5.79M5.47M9.40M11.39M
Cash from OperationsCash from Ops.
-29.97M-30.91M-42.63M-32.91M-46.31M-37.95M-48.45M-18.47M-41.13M26.69M-41.95M-39.70M-42.18M-48.75M-61.09M-63.16M-57.38M-67.83M-71.91M-96.57M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.86M0.85M1.26M1.35M1.43M1.42M1.43M1.44M1.43M1.82M1.93M2.16M3.71M3.49M3.56M2.70M2.20M1.87M1.98M1.56M
Depreciation & Amortization (CF)Dep. & Amort.
0.70M0.77M0.99M1.30M1.50M1.62M1.75M1.90M1.95M1.93M2.04M2.33M2.39M2.55M2.35M2.24M2.03M2.12M2.20M2.25M
Change in Working Capital
Change in ReceivablesChange Receivables
2.00M-2.00M
Change in Account PayablesChange Payables
-1.39M0.86M-0.10M1.85M-0.76M-0.90M0.40M-2.24M-1.20M4.65M-0.93M-2.54M1.09M7.58M-3.21M-2.68M2.23M3.02M-0.46M1.87M
Change in Accured ExpensesChange Accured Exp.
3.53M3.38M-3.32M6.14M1.36M3.30M-6.91M2.26M4.70M3.08M3.59M-6.84M6.04M9.02M6.94M-7.01M6.34M11.04M4.12M-15.25M
Other Working Capital ChangesOther WC Changes
-9.25M3.60M-3.62M-9.43M-9.29M-4.28M-9.18M-5.68M-16.47M50.84M-12.59M4.91M-7.59M-13.28M-9.83M-5.68M-7.89M-13.58M-1.25M-7.04M
Investing Activities
Capital ExpendituresCapex
1.86M0.86M3.47M2.79M3.42M2.56M2.28M1.08M2.46M2.58M2.88M1.94M2.35M2.10M3.48M2.67M2.71M5.13M1.70M1.28M
Change in Acquisitions & DivestmentsChange Acquisitions
64.21M55.02M58.75M62.81M72.77M84.48M40.99M105.62M99.82M76.61M93.20M95.98M110.83M159.50M139.20M142.34M156.19M179.81M133.15M119.56M
Cash from Investing ActivitiesCash from Investing
-12.23M-36.52M40.03M-4.76M-63.08M55.01M16.07M43.83M22.77M-14.37M35.51M-131.07M-21.34M-140.82M25.53M71.50M50.48M0.35M-123.83M93.00M
Financing Activities
Other financing activitiesOther financing
1.02M1.06M-92.99M1.45M0.78M1.27M2.34M-1.47M1.25M0.98M1.60M
Cash from Financing ActivitiesCash from Financing
1.55M0.50M1.49M0.43M115.41M-0.14M1.48M0.03M1.70M0.01M1.62M237.75M45.77M200.52M1.47M0.01M1.16M236.01M19.98M0.07M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
2.34M0.92M
Net Equity Issued and RepurchasedNet Equity Issued
50.20M42.90M95.40M18.00M
Additional items
Change in Cash
-40.65M-66.93M-1.11M-37.25M6.02M16.92M-30.90M25.39M-16.65M12.32M-4.81M66.98M-17.75M10.95M-34.08M8.34M-5.75M168.52M-175.76M-3.51M
Free Cash FlowFCF
-31.84M-31.77M-46.10M-35.70M-49.73M-40.52M-50.73M-19.55M-43.59M24.10M-44.84M-41.64M-44.52M-50.86M-64.57M-65.84M-60.10M-72.96M-73.61M-97.85M
Net Cash FlowNCF
-40.65M-66.93M-1.11M-37.25M6.02M16.92M-30.90M25.39M-16.65M12.32M-4.81M66.98M-17.75M10.95M-34.08M8.34M-5.75M168.52M-175.76M-3.51M